Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
The analyst sees zele with a potential high-opportunity Nectin-4 conjugate for solid tumors, with an estimated ~$2 billion at peak global sales in 2033.RBC Capital initiated coverage on Bicycle Therapeutics PLC (NASDAQ:BCYC), noting an advantage in oncology and beyond.
RBC Capital开始对Bicycle Therapeutics PLC（纳斯达克: BCYC）进行覆盖，指出其在肿瘤学和其他领域具有优势。
The analyst writes the company's lead program, Zelenectide pevedotin (zele, formerly BT8009), shows potential to compete in metastatic urothelial cancer (mUC) due to similar objective response rates and fewer adverse events compared to Pfizer Inc's (NYSE:PFE) Seagen Inc. drug, Padcev.
分析师指出，该公司的主导项目Zelenectide pevedotin（zele，以前称为BT8009）在转移性膀胱癌（mUC）中显示出与辉瑞公司（纽交所:PFE）的Seagen Inc.药物Padcev相似的客观反应率和更少的不良事件竞争潜力。
The improved safety profile of Zelenectide could result in greater antitumor durability, a key differentiator from Padcev.
Zelenectide更好的安全性能可能会导致更长的抗肿瘤耐药性，与Padcev不同的一个关键点。
The analyst sees zele with a potential high-opportunity Nectin-4 conjugate for solid tumors, with an estimated ~$2 billion at peak global sales in 2033.
分析师认为，对于实体肿瘤，zele具有潜在的高机会Nectin-4结合物，预计2033年全球销售额将达到约20亿美元。
RBC writes, "Commercialization opportunities in non-mUC indications are likely less competitive and offer additional upside to zele."
RBC表示:"非转移性膀胱癌的商业机会可能竞争较小，并为zele提供额外的增长空间。"
The analyst initiates with an Outperform rating and a price target of $35.
分析师给予Outperform评级和35美元的目标股价。
The RBC Capital analyst views the regulatory path for Zele as de-risked following FDA alignment on the Duravelo-2 trial. RBC's proprietary oncologist survey highlights strong demand for a safer Nectin-4 drug conjugate.
RBC Capital分析师认为，在FDA的Duravelo-2试验上达成一致后，Zele的监管路径已减少风险。RBC的专有肿瘤学家调查强调，对于更安全的Nectin-4结合物存在强烈的需求。
The analyst also notes Zele's potential therapeutic value in additional solid tumor indications, such as triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC), which Padcev has yet to address.
分析师还指出，Zele在其他实体肿瘤指标中具有潜在的治疗价值，例如三阴性乳腺癌（TNBC）和非小细胞肺癌(NSCLC)，这些指标是Padcev尚未解决的。
The analyst highlights the strong potential of Bicycle Therapeutics' pipeline, which includes two additional clinical-stage candidates. Early signs of activity and safety indicate promise for both candidates in treating solid tumors.
分析师强调了Bicycle Therapeutics的产品线的巨大潜力，其中包括两个其他临床阶段候选药物。早期的活动和安全性迹象表明这两个候选药物在治疗实体瘤方面具有潜力。
The Bicycle platform has been proven through clinical data from its internal pipeline and various external partnerships, generating over $200 million in non-dilutive capital. Future value creation is anticipated from next-generation Bicycle Toxin Conjugates (BTCs), radiopharmaceutical applications, and expansion into areas beyond oncology.
通过其内部产品线和各种外部合作伙伴关系的临床数据，Bicycle平台已经得到验证，产生了超过2,000万美元的非稀释性资本。未来的价值创造预计将来自下一代Bicycle毒素偶联物（BTCs），放射药物应用以及扩展到肿瘤以外的领域。
As of June 30, 2024, cash and cash equivalents were $961.4 million, which is expected to provide a cash runway into the second half of 2027.
截至2024年6月30日，现金及现金等价物为96140万美元，预计足够支持至2027年下半年。
Price Action: BCYC stock is up 1.27% at $20.69 at the last check on Friday.
价格走势：BCYC股票在上周五最后一次查询时上涨1.27%，报20.69美元。
- FDA Battles Backlog of Drug Factory Inspections Since COVID-19.
- 美国食品药品监督管理局在COVID-19疫情以来一直与待审的药品工厂巡查堆积进行斗争。
